Summary
Amgen Inc. filed an 8-K report on October 5, 2009, to announce the termination of a material definitive agreement. Specifically, the Enbrel Supply Agreement, originally dated November 5, 1998, and subsequently amended, was terminated by all parties involved on September 30, 2009. The agreement involved Amgen's subsidiary, Immunex Corporation, along with Wyeth and Boehringer Ingelheim Pharma KG. This termination is a significant event for investors as Enbrel is a key product for Amgen. While the filing does not detail the reasons for termination or the specific impact on future supply or sales, it signals a change in the contractual arrangements surrounding the distribution or manufacturing of this important biologic therapy. Investors should closely monitor subsequent filings and company communications for further details on the implications of this termination on Amgen's operations and financial performance.
Key Highlights
- 1Amgen announced the termination of the Enbrel Supply Agreement.
- 2The termination was effective September 30, 2009.
- 3The agreement involved Immunex Corporation (an Amgen subsidiary), Wyeth, and Boehringer Ingelheim Pharma KG.
- 4The original agreement dated back to November 5, 1998, and had been amended.
- 5This filing is a Form 8-K, indicating a material event requiring prompt disclosure.
- 6The termination involves a key drug for Amgen, Enbrel.